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Original StudieS
Background: Uncertainty about the presence of infection results in unnec-
essary and prolonged empiric antibiotic treatment of newborns at risk for 
early-onset sepsis (EOS). This study evaluates the impact of this uncertainty 
on the diversity in management.
Methods: A web-based survey with questions addressing management of 
infection risk-adjusted scenarios was performed in Europe, North America, 
and Australia. Published national guidelines (n = 5) were reviewed and com-
pared with the results of the survey.
Results: 439 Clinicians (68% were neonatologists) from 16 countries com-
pleted the survey. In the low-risk scenario, 29% would start antibiotic therapy 
and 26% would not, both groups without laboratory investigations; 45% 
would start if laboratory markers were abnormal. In the high-risk scenario, 
99% would start antibiotic therapy. In the low-risk scenario, 89% would dis-
continue antibiotic therapy before 72 hours. In the high-risk scenario, 35% 
would discontinue therapy before 72 hours, 56% would continue therapy for 
5–7 days, and 9% for more than 7 days. Laboratory investigations were used 
in 31% of scenarios for the decision to start, and in 72% for the decision 
to discontinue antibiotic treatment. National guidelines differ considerably 
regarding the decision to start in low-risk and regarding the decision to con-
tinue therapy in higher risk situations.
Conclusions: There is a broad diversity of clinical practice in management of 
EOS and a lack of agreement between current guidelines. The results of the 
survey reflect the diversity of national guidelines. Prospective studies regard-
ing management of neonates at risk of EOS with safety endpoints are needed.
Key Words: early-onset sepsis, newborn disease, sepsis, biological markers, 
sepsis diagnosis
(Pediatr Infect Dis J 2016;35:494–500)
Infections are globally the single largest cause of neonatal deaths.1 Up to 15% of all term and late-preterm neonates are evaluated 
for suspected early-onset neonatal sepsis (EOS), and up to 10% are 
treated with intravenous antibiotics for suspected bacterial sepsis 
within the first 3 days of life, consuming a significant amount of 
resources in neonatal units worldwide.2–4 However, the incidence 
of culture-proven EOS in term and late preterm neonates is less 
than 0.1%.2–6 Early diagnosis and treatment of EOS are essential 
to prevent severe and life threatening complications. Nevertheless, 
diagnosis is difficult because of the often subtle, nonspecific clini-
cal presentation and low predictive values of any biomarkers.3,7–9 
Uncertainty about the presence of infection may result in unneces-
sary and prolonged empiric antibiotic treatment.10
Guidelines play a crucial role in supporting decision-making 
for this vulnerable group of patients. Recently published reports of 
effects after implementation of new guidelines demonstrate the chal-
lenges those entail.11,12 Best practice and future guidelines should 
aim at reducing the number of neonates unnecessarily treated with 
antibiotics and the duration of treatment although capturing 100% of 
neonates with proven EOS. In view of the significant impact of treat-
ment of EOS on the health care system, it is important to know the 
current standard of practice. Knowledge regarding the current stand-
ard is critical for the development of future studies and strategies to 
improve management of newborns at risk for EOS. The aim of this 
study was to describe the current management of suspected EOS in 
term and late preterm infants among clinicians in different countries 
and on different continents by conducting a survey and comparing 
the results to a review of the recent national guidelines for EOS.
MATERIALS AND METHODS
International Survey
Between March 2011 and March 2012, a web-based survey 
(SurveryMonkey, SurveyMonkey, Paolo Alto, CA), developed by the 
NEonatal Sepsis Trial NETwork (NEST-NET, www.nest-net.org), 
was sent by e-mail to pediatricians and neonatologists in Europe, 
North America and Australia. The questionnaire was drafted by 2 
authors (S.P., M.S.) and revised after review by the group of authors. 
The selection of countries and regions for email distribution of the 
survey was based on the national (United Kingdom, Canada, the 
Netherlands) or regional (all other countries) network of the NEST-
NET group members. All potential participants were e-mailed back-
ground information on the study with an invitation to anonymously 
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participate. Consent was implied upon completion of the study ques-
tionnaire. Those who did not respond received a reminder within 2 
months. Response rates were calculated by comparing the number 
of sent e-mails with the number of participants who answered the 
questionnaires. Ethical approval for the study was obtained from the 
Hamilton Integrated Research Ethics Board, McMaster University, 
Hamilton Health Sciences, Canada.
There were 3 sections of the questionnaire: 6 questions 
regarding clinical management, 2 questions regarding use of labora-
tory investigations (biomarkers, cultures) and 4 demographic items. 
Questions regarding the decision to start and discontinue antibiotic 
therapy were introduced by scenarios rated as low, medium and 
high risk for neonatal EOS, based on risk factors and clinical signs 
of infection (Table 1). The possible answers for the decision to start/
discontinue antibiotic therapy were investigating the dependency 
on laboratory investigations. Additionally, we determined the pro-
portion of physicians using newer infection markers such as pro-
calcitonin (PCT) and interleukins, compared with conventional 
markers such as complete blood count (CBC) and C-reactive pro-
tein (CRP). Questions about demographic factors with a potential 
influence on management of suspected EOS were asked (country, 
level of training, number of patients with EOS treated by this physi-
cian per month and recent experiences of fatal cases).
Review of Guidelines
Published national guidelines in English language were 
selected for review. Guidelines were searched in PubMed using the 
terms “neonatal early-onset sepsis” and “guideline or recommenda-
tion” on December 1, 2014. The most recent available version was 
selected, and the review was focused on (i) the decision to start 
antibiotic treatment for suspected EOS, (ii) duration of antibiotic 
therapy and (iii) use of laboratory markers for management of sus-
pected EOS. Comparison of the guidelines was done by 2 authors 
(W.v.H., M.S.), to describe the variation in current guidelines on the 
management of suspected EOS.
Comparison
The survey results were compared with the published national 
guidelines using the infection risk-adjusted scenarios. For each 
country, the national recommendations for each specific scenario 
TABLE 1. Scenarios Regarding the Start/Discontinuation of Antibiotic Therapy, Rated as Low/Medium/High Risk of 
Infection
Severity of Risk Case Description Possible Interventions
Start of antibiotic therapy
  Low risk (solely risk  
factors)
•	 Spontaneous vaginal delivery
•	 Two maternal risk factors for infection: maternal fever 
38.5°C, rupture of membranes for 28 h, GBS negative
• Term newborn without clinical signs of infection 2 h after 
delivery
A.	 Start antibiotic therapy, laboratory  
investigations not necessary for decision
B.	 No antibiotic therapy, laboratory  
investigations not necessary for decision
C.	 Start antibiotic therapy if laboratory  
investigations are abnormal  Medium risk (clinical  
signs without  
risk factors)
•	 Spontaneous vaginal delivery
•	 No maternal risk factors for infection
•	 Term newborn with respiratory distress (respiratory rate 
70/min, retractions, intermittent grunting, SpO2 95% in 
room air), pale, capillary refill time 3 seconds. All signs 
detected 2 h after delivery
  High risk (risk factors  
and clinical signs)
•	 Spontaneous vaginal delivery
•	 Two maternal risk factors for infection: maternal fever 
38.5°C, rupture of membranes for 28 h, GBS negative
•	 Term newborn with respiratory distress (respiratory rate 
70/min, retractions, intermittent grunting, SpO2 95% in 
room air), pale, capillary refill time 3 seconds. All signs 
detected 2 h after delivery.
Discontinuation of antibiotic therapy (duration)
  Low risk (risk factors, 
clinical signs resolved 
early on the first day)
•	 Spontaneous vaginal delivery
•	 Two maternal risk factors for infection: maternal fever 
38.5°C, rupture of membranes for 28 h, GBS negative
•	 Term newborn with respiratory distress (respiratory rate 
70/min, retractions, intermittent grunting, SpO2 95% in 
room air), pale, capillary refill time 3 s.
•	 All clinical signs detected 2 h after delivery and resolved 
6 h later
•	 Cultures remained negative (blood, cerebrospinal fluid)
A.	 Antibiotic therapy ≤ 72 h, independent of 
laboratory investigations (except cultures)
B.	 Antibiotic therapy ≤ 72 h, but dependent  
on laboratory investigations (except cultures)
C.	 Antibiotic therapy 5 to a maximum of  
7 d, independent of laboratory  
investigations (except cultures)
D.	 Antibiotic therapy 5 to a maximum of  
7 d, but dependent on laboratory  
investigations (except cultures)
E.	 Antibiotic treatment ≥ 7 d, independent of 
laboratory investigations (except cultures)
F.	 Antibiotic treatment ≥ 7 d, but dependent 
on laboratory investigations (except cultures)
  Medium risk (no risk  
factors, clinical signs 
resolved on the second 
day)
•	 Spontaneous vaginal delivery
•	 No maternal risk factors for infection
•	 Term newborn with respiratory distress (respiratory rate 
70/min, retractions, intermittent grunting, SpO2 95% in 
room air), pale, capillary refill time 3 s.
•	 All signs detected 2 h after delivery and resolved after 
24–36 h
•	 Cultures remained negative (blood, cerebrospinal fluid)
  High risk (risk factors, 
clinical signs resolved  
late after the  
third day)
•	 Spontaneous vaginal delivery
•	 Two maternal risk factors for infection: maternal fever 
38.5°C, rupture of membranes for 28 h, but GBS negative
•	 Term newborn with respiratory distress (respiratory rate 
70/min, retractions, intermittent grunting, SpO2 95% in 
room air), pale, capillary refill time 3 s.
•	 All signs detected 2 h after delivery and resolved after 72 h
•	 Cultures remained negative (blood, cerebrospinal fluid)
GBS indicates group B streptococcus.
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regarding decision to start/stop antibiotic therapy and the dependency 
on laboratory results were compared with the results of the survey.
Statistics
Completed surveys were entered and tabulated by Survey 
monkey. Descriptive analyses were used for comparison of answers. 
Answers were compared using χ2 tests with 2 degrees of freedom. A 
P value <0.05 was considered statistically significant with a confi-
dence interval at 95%.
RESULTS
Survey
The demographics of the participants are shown in Table 2. 
A total of 439 pediatricians and neonatologists responded; 367 
(83.6%) respondents answered all 11 questions. The response 
rate was calculated in 6 countries: Australia, 30%; Czech Repub-
lic, 61%; Netherlands, 20%; Norway, 40%; Slovakia, 80% and 
Switzerland, 40%. In all other countries, the response rate was 
not calculated because of the unknown number of physicians 
approached.
When asking about initiating antibiotic treatment in the 
low-risk scenario, 29% would start and 26% would not start treat-
ment irrespective of laboratory investigations; 45% would start 
treatment if laboratory markers were abnormal. In the high-risk 
scenario, 99% of the respondents would start antibiotic therapy 
(Table 3). Regarding the discontinuation of antibiotic therapy, 89% 
of respondents would discontinue therapy before 72 hours in the 
low-risk scenario. In the high-risk scenario, 35% of respondents 
would discontinue therapy before 72 hours, 56% of respondents 
would continue therapy for 5–7 days, and 9% of respondents for 
more than 7 days (Table 3). Overall, participants based their deci-
sion to start antibiotic treatment significantly less often on labo-
ratory investigations than their decision to discontinue antibiotic 
treatment (31% vs. 72%, P < 0.0001). The majority of respondents 
relied on conventional infection parameters such as CBC (92%) 
and/or CRP (92%). Only a minority used newer markers of inflam-
mation such as PCT (17%) and/or interleukins (9%; CRP vs. PCT: 
P < 0.0001). Almost all respondents (98%) indicated drawing blood 
cultures before starting antibiotic therapy. Most respondents per-
formed a lumbar puncture depending on the clinical presentation 
(81%), whereas only 3% always obtained a cerebrospinal fluid 
culture. Regular use of body surface cultures (including umbili-
cal stump or skin) was reported by 31% and regular use of urine 
cultures by 26%. The results were not influenced by demographic 
factors. We observed a marked variability in the decision whether 
to start/discontinue antibiotic therapy in low- and high-risk sce-
nario depending on countries of origin (Table 4).
Review of National Guidelines
Table 5 summarizes the most important aspects focus-
ing on initiation and duration of antibiotic therapy in 5 national 
guidelines (Canada, United States, United Kingdom, Switzer-
land, Belgium).13–17 In low-risk scenarios such as chorioam-
nionitis without clinical signs, 2 guidelines (US and Belgium) 
recommend immediate treatment; one guideline (Canada) rec-
ommends treatment if the laboratory results are abnormal, and 2 
guidelines (United Kingdom and Switzerland) advice to observe 
the neonate. In low-risk scenarios with other risk factors without 
clinical signs, one guideline (US) recommends treatment if the 
laboratory results are abnormal, 1 guideline (United Kingdom) 
recommends treatment if there are ≥ 2 risk factors, and 3 guide-
lines (Canada, Switzerland and Belgium) advice to observe the 
neonate. All 5 clinical guidelines agree to treat newborns with 
clinical signs possibly related to infection. The guidelines uni-
formly recommend re-evaluating the need for further antibiotic 
therapy after 36–48 hours and discontinuing antibiotic therapy 
if infection is unlikely. On the other hand, advice on duration of 
treatments in newborns with prolonged clinical signs possibly 
related to infection or increased levels of infection markers is 
either unspecific or not provided. All guidelines advocate using 
conventional infection markers (CBC and CRP) and 1 out of 5 
includes PCT.17
Comparison of Survey with Review of Guidelines
In 4 countries (Switzerland, Canada, US and United King-
dom), survey results can be compared with their national guidelines 
(Table 3). The majority of the respondents in the survey followed 
their national guidelines regarding the decision to start/discontinue 
antibiotic therapy.
DISCUSSION
This study surveyed management practices of EOS in high-
income countries across Europe, North America and Australia and 
compared the results with published guidelines. As expected, we 
found a broad agreement within the survey as well as in the review 
of the guidelines to start empiric antibiotic treatment in high-risk 
TABLE 2. Demographics of Participants in Percentage of All Respondents (n = 439)
Country Level of Training
Number of Treated Patients with 
Suspected EOS; Per  
Physician Per Month in %
Number of Recent Fatal 
Cases of EOS in Last  
12 Mo in %
13.9% United Kingdom 68.3% Board-certified neonatologists 11.0% Low caseload (0–2 cases) 44.4% None
12.3% The Netherlands  36.7% 1–2 Fatal cases 
10.5% Czech Republic 6.2% Trainees in neonatology 40.1% Medium caseload (2–10 cases) 5.0% ≥ 3 Fatal cases 
9.6% US
6.2% Switzerland 11.8% Pediatricians 35.5% High caseload (>10 cases) 13.9% Not known
5.7% Canada 13.7% Not known 13.4% Not known
5.5% France
5.5% Slovakia
4.6% Australia
4.3% Norway
3.0% Sweden
2.5% Other countries (Germany, 
Spain, Belgium, Finland, 
Poland)
16.4% Not known
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situations such as newborns with clinical signs suggestive of 
infection.13–17 On the other hand, we found a high diversity in the 
approach to when to start antibiotic therapy in low-risk situations 
such as asymptomatic infants born to mothers with risk factors for 
EOS. The differences in the decision to start antibiotic therapy in 
low-risk situations raise the question of justifiable risk threshold for 
laboratory investigations and/or treatment. A retrospective analy-
sis estimated that in order to ensure treatment of all proven cases 
of EOS within a given risk stratum in term and late-preterm new-
borns, the number needed to treat (NNT) in the high-risk group 
(empirical antibiotic therapy) is 118, the NNT in the medium-risk 
group (entering a pathway of observation and clinical investiga-
tions) is 823, and the NNT in the low-risk group (observation only) 
is 9370.18 These numbers juxtapose the reported mortality of proven 
EOS for term and late preterm infants between 1.3% and 1.7%.2,19 
Accepting the reported threshold means treating more than 6900 or 
performing laboratory investigations in more than 48000 newborns 
at risk for EOS to save 1 child who would die because of sepsis. The 
societal and economic justification for any numbers remains within 
the respective national health system acknowledging national dif-
ferences as percentage of group B streptococcus screening, home 
births and follow-up strategies. But beside the financial burden and 
use of resources, antibiotic treatment of asymptomatic newborns 
raises the question of the safety of this strategy. The increased risk 
on the development of necrotizing enterocolitis, late-onset sepsis 
and death from prolonged antibiotic treatment of premature infants 
is well documented.20–23 Additionally, recent cohort studies report 
an increased risk of recurrent wheezing demanding corticosteroid 
therapy within the first few years of age for infants treated with 
antibiotics in the first week of life.24,25
TABLE 3. Comparison of National Survey Results with Their National Guidelines Regarding the Decision to  
Start/Discontinuation of Antibiotic Therapy
Start of antibiotic therapy
Severity of risk Country Advice national guideline
Survey results in % of respondents
Observe
Start therapy  
independent on 
laboratory  
results
Start therapy 
dependent on 
laboratory  
results
  Low risk (solely risk 
factors)
Overall Not applicable 26% 29% 45%
Canada Observe 40% 28% 32%
US Treat, if laboratory results are abnormal 10% 26% 64%
United Kingdom Treat 5% 79% 16%
Switzerland Observe 56% 7% 37%
  Medium risk (no risk 
factors, clinical signs 
possible related to 
infection)
Overall Not applicable 10% 57% 33%
  High risk (risk factors 
and clinical signs)
Overall Not applicable 1% 86% 13%
Canada Treat 0% 96% 4%
US Treat 0% 98% 2%
United Kingdom Treat 0% 100% 0%
Switzerland Treat 4% 85% 1%
Discontinuation of antibiotic therapy (duration)
Severity of risk Country
Advice national guideline:
Survey results in % of respondents  
(% that is dependent on laboratory results)
Re-evaluation at 48 h and
Discontinues 
≤72 h
Continues  
for 5–7 d
Continues  
for >7 d
Low risk (risk  
factors, clinical  
signs resolved early 
on the first day)
Overall Not applicable 89% (68%) 10% (7%) 1% (0.3%)
Canada Discontinue if infection unlikely, laboratory  
not mentioned
88% (48%) 8% (8%) 4% (0%)
US Discontinue if infection unlikely, laboratory 
results helpful
98% (50%) 2% (2%) 0%
United Kingdom Discontinue if infection unlikely and CRP  
reassuring
87% (77%) 13% (10%) 0%
Switzerland Discontinue if infection unlikely, laboratory 
results helpful
93% (52%) 7% (7%) 0%
Medium risk (clinical  
signs possible related 
to infection resolved 
after 24–36 h)
Overall Not applicable 74% (56%) 26% (18%) 1% (0.3%)
High risk (risk  
factors, clinical  
signs resolved late 
after the third day)
Overall Not applicable 35% (28%) 56% (34%) 8% (5%)
Canada Discontinue if infection unlikely, continue for at 
least 5 d if progress consistent with sepsis
28% (24%) 60% (44%) 12% (4%)
US Discontinue if infection unlikely, laboratory 
results helpful
45% (24%) 45% (12%) 10% (5%)
United Kingdom Discontinue if infection unlikely + CRP  
reassuring, continue 7 d if progress is  
consistent with sepsis
33% (26%) 66% (31%) 2% (2%)
Switzerland Discontinue if infection unlikely, laboratory 
results helpful
30% (15%) 63% (41%) 7% (4%)
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We found a high agreement to discontinue antibiotic ther-
apy before 72 hours in the low-risk scenario in the survey and 
in all guidelines.13–17 On the other hand, our results demonstrate 
a high diversity regarding duration of antibiotic therapy in the 
high-risk setting. Blood cultures, which are the gold standard to 
diagnose sepsis, are often falsely negative because of a limited 
volume of blood drawn for culture and/or intrapartum antibi-
otics administered to the mother.26 Serial negative laboratory 
parameters such as neutrophil values and indices, CRP or PCT 
have shown a high–negative-predictive value and may serve to 
decide when to discontinue empirical antibiotic treatment.27–29 
However, clinical situations with elevated laboratory markers 
of inflammation or prolonged clinical signs suggestive of infec-
tion are far more common than culture-proven infection and 
may have unintended consequences as the illustrative example 
of the 2012 guidelines of the American Academy for Pediatrics 
(AAP) revealed.16 The AAP recommends that all asymptomatic 
neonates born to mothers with signs of chorioamnionitis should 
receive antibiotic therapy if the CBC and/or the CRP are abnor-
mal. A retrospective population based data analysis showed that 
through implementation of the guideline, 96% of empirically 
treated neonates born to mothers with signs of chorioamnionitis 
were clinically well, but 20% were treated with prolonged anti-
biotic therapy for at least seven days based solely on abnormal 
laboratory tests.11 Recently, authors of the AAP guidelines 2012 
made a statement in response to this publication: “Commonly 
used laboratory tests have a limited positive predictive accuracy 
and should never be used as a rational to continue antibiotic 
treatment in an otherwise healthy term infant at 48 to 72 hours 
of life.”30 The diversity with regards to duration of antibiotic 
therapy in higher risk situations raises the question, what are 
safe strategies to minimize duration of antibiotic therapy with-
out under-treatment of truly septic neonates? Currently, the 
duration of antibiotic therapy is controversial even for proven 
infections.31–33 Prospective, international, multicenter trials 
studying newer infection markers with a safety endpoint may 
be helpful in answering this question.34 As shown in our survey, 
clinicians are ready to discontinue antibiotic therapy depend-
ing on infection markers. This is in agreement with previous 
reviews.7–9,35
Interpretation of national-based data from our survey 
alone is not possible because of the low number of participants 
in each country. Nevertheless, the data reflect the trends of the 
recommendations of the national guidelines. The guidelines of 
the United Kingdom and US recommend treating newborns in 
our low-risk scenario and more than 90% of respondents in the 
United Kingdom and US agree based on their responses.15,16 
The Swiss guideline only recommends observing newborns in 
our low-risk scenario and only 44% of clinicians in Switzer-
land would start antibiotic treatment, most of them if labora-
tory markers were abnormal.17 Interestingly, there is no obvious 
geographically common pattern for North America or Europe. 
The agreement between respondents and the national guidelines 
suggests that guidelines are relevant in the decision-making 
process of clinicians at the bedside. However, consequences 
of published guidelines may be different than expected. After 
implementation of the National Institute for Health and Care 
Excellence (NICE) guideline in the United Kingdom recom-
mending measurement of CRP concentration 18–24 hours after 
the start of antibiotic therapy, a report showed a greater consist-
ency in management, but more investigations including lumbar 
punctures, and a greater length of stay for newborns with sus-
pected EOS.12 Guidelines have to be as clear and concise as pos-
sible, and implementation of new guidelines has to be followed 
by population-based studies asking for impact and unintended 
adverse effects.
This study has limitations. The low and only partially 
known response rate may introduce selection bias. Whereas 
response rates are usually judged as measurement of response 
bias, a recently published review of pediatric surveys shows 
evidence that this may not be necessarily be the case.36 The 
impact of a possible selection bias is small if the approached 
group of participants is closely targeted as in our survey.36–38 
Another limitation is the low number of participants per country. 
Therefore, interpretation of national-based data from the survey 
alone is not possible.
CONCLUSIONS
There are large differences between clinicians in the man-
agement of term and late preterm neonates at risk for EOS. In par-
ticular, this was observed regarding the decision to start antibiotic 
therapy in low-risk situations and the decision on duration of anti-
biotic therapy in high-risk situations. Dependence on laboratory 
investigations is low for decisions to start and high for decisions 
to discontinue antibiotic therapy. Only a minority of respondents 
TABLE 4. Geographical Distribution of Starting and Discontinuation of Antibiotic Therapy (in %, Dependent and 
Independent on Lab Combined)
Country
Number of 
Respondents
Start of Antibiotic Therapy Discontinuation of Antibiotic Therapy >72 h (duration)
Low Risk (Solely 
Risk Factors), %
Medium Risk  
(No Risk Factors, 
Clinical Signs 
Possible Related to 
Infection), %
High Risk  
(Risk Factors 
and Clinical 
Signs), %
Low Risk  
(Risk Factors, 
Clinical Signs 
Resolved Early 
on the First 
Day), %
Medium Risk 
(Clinical Signs 
Possible Related 
to Infection 
Resolved After 
24–36 h), %
High Risk  
(Risk Factors,  
Clinical Signs 
Resolved Late After 
the Third Day), %
United Kingdom 61 95.1 96.7 100 14.1 29.5 77.2
The Netherlands 54 55.6 94.4 100 3.8 26.0 64.8
Czech Republic 46 50.0 89.1 100 8.7 37.0 76.1
US 42 90.5 92.9 97.6 2.4 23.8 55.8
Switzerland 27 44.4 77.8 96.3 7.4 18.5 71.4
Canada 25 60.0 84.0 96.0 12.0 16.0 72.0
France 24 91.7 100 100 20.9 25.1 76.6
Slovakia 24 95.8 91.7 100 16.9 37.5 66.7
Australia 20 70.0 90.0 100 20.0 15.0 45.0
Norway 19 73.7 84.2 100 5.3 31.6 78.4
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uses newer infection markers such as PCT and interleukins. A 
discussion leading to terms of a threshold to treat neonates with a 
low infection risk, prospective studies of strategies regarding early 
discontinuation of unnecessary antibiotic therapy with safety end-
points acknowledging different backgrounds of health care systems 
and clear and concise guidelines followed by research to study the 
impact are mandatory to improve management of term and late pre-
term newborns at risk for EOS.
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